Elsevier

The Lancet

Volume 391, Issue 10135, 26 May–1 June 2018, Pages 2128-2139
The Lancet

Articles
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

https://doi.org/10.1016/S0140-6736(18)30789-XGet rights and content

Summary

Background

The estimation of risk of recurrence for patients with colon carcinoma must be improved. A robust immune score quantification is needed to introduce immune parameters into cancer classification. The aim of the study was to assess the prognostic value of total tumour-infiltrating T-cell counts and cytotoxic tumour-infiltrating T-cells counts with the consensus Immunoscore assay in patients with stage I–III colon cancer.

Methods

An international consortium of 14 centres in 13 countries, led by the Society for Immunotherapy of Cancer, assessed the Immunoscore assay in patients with TNM stage I–III colon cancer. Patients were randomly assigned to a training set, an internal validation set, or an external validation set. Paraffin sections of the colon tumour and invasive margin from each patient were processed by immunohistochemistry, and the densities of CD3+ and cytotoxic CD8+ T cells in the tumour and in the invasive margin were quantified by digital pathology. An Immunoscore for each patient was derived from the mean of four density percentiles. The primary endpoint was to evaluate the prognostic value of the Immunoscore for time to recurrence, defined as time from surgery to disease recurrence. Stratified multivariable Cox models were used to assess the associations between Immunoscore and outcomes, adjusting for potential confounders. Harrell's C-statistics was used to assess model performance.

Findings

Tissue samples from 3539 patients were processed, and samples from 2681 patients were included in the analyses after quality controls (700 patients in the training set, 636 patients in the internal validation set, and 1345 patients in the external validation set). The Immunoscore assay showed a high level of reproducibility between observers and centres (r=0·97 for colon tumour; r=0·97 for invasive margin; p<0·0001). In the training set, patients with a high Immunoscore had the lowest risk of recurrence at 5 years (14 [8%] patients with a high Immunoscore vs 65 (19%) patients with an intermediate Immunoscore vs 51 (32%) patients with a low Immunoscore; hazard ratio [HR] for high vs low Immunoscore 0·20, 95% CI 0·10–0·38; p<0·0001). The findings were confirmed in the two validation sets (n=1981). In the stratified Cox multivariable analysis, the Immunoscore association with time to recurrence was independent of patient age, sex, T stage, N stage, microsatellite instability, and existing prognostic factors (p<0·0001). Of 1434 patients with stage II cancer, the difference in risk of recurrence at 5 years was significant (HR for high vs low Immunoscore 0·33, 95% CI 0·21–0·52; p<0·0001), including in Cox multivariable analysis (p<0·0001). Immunoscore had the highest relative contribution to the risk of all clinical parameters, including the American Joint Committee on Cancer and Union for International Cancer Control TNM classification system.

Interpretation

The Immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer. These results support the implementation of the consensus Immunoscore as a new component of a TNM-Immune classification of cancer.

Funding

French National Institute of Health and Medical Research, the LabEx Immuno-oncology, the Transcan ERAnet Immunoscore European project, Association pour la Recherche contre le Cancer, CARPEM, AP-HP, Institut National du Cancer, Italian Association for Cancer Research, national grants and the Society for Immunotherapy of Cancer.

Introduction

Prognosis of patients with resectable colorectal cancer relies on histopathological criteria of tumour invasion according to the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) TNM classification system and on features of tumour-cell differentiation.1, 2, 3 This anatomy-based system provides useful but incomplete prognostic information.4 New ways to classify cancer that focuse on tumour cells, molecular pathways, mutation status, and tumour gene expression-based stratification4, 5 only have a moderate prediction accuracy and limited clinical usefulness.

In-situ immune cell infiltrate in tumours is associated with a favourable prognostic effect.4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 In colorectal cancer, we have shown that time to recurrence and overall survival strongly correlate with the strength of the in-situ adaptive immune reaction8, 13, 17, 20, 21 in the colon tumour and the invasive margin.22 We have previously characterised the subtypes of immune cells that infiltrate tumours23 and proposed that the intra-tumoral immune contexture (ie, type, functional orientation, density, and location of immune cells) of solid tumours could be a dominant determinant of clinical outcome.7, 8 We showed the usefulness of a derived immune score termed Immunoscore to predict clinical outcome in patients with early20 and advanced24, 25 stage colorectal cancer. The consensus Immunoscore is a scoring system to summarise the density of CD3+ and CD8+ T-cell effectors within the tumour and its invasive margin.

Research in context

Evidence before this study

We searched MEDLINE via PubMed for evidence available by Jan 1, 2018, for an association between immune cell infiltrates of tumours and prognosis in various cancer types. 250 published articles implicating cytotoxic T cells, memory T cells, and T-helper cell subpopulations in prognosis of cancer patients were retrieved (28 different cancer types were analysed). Tumour infiltration by cytotoxic CD8+ T cells was associated with a good prognosis in 98% of the studies. By contrast, other T-helper subpopulations had a good or a bad prognostic effect depending on the method used and on the cancer types. Colorectal cancer was the most studied cancer type. The quantification of immune infiltrates had a prognostic importance superior to that of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) TNM classification system. Multiple ways to classify cancer, colorectal cancer in particular, have been proposed. These rely on tumour cell characteristics, such as morphology, molecular pathways, mutation status, tumour cell origin, and tumour gene expression. Despite the importance of the intratumour immune reaction to predict patients at high risk and low risk of recurrence and death, no immune marker is used in the classification of colorectal cancer at present.

Added value of this study

After the first World Immunotherapy Council meeting on Feb 21–24, 2012, bringing together 17 cancer international organisations, a decision was made, together with the Society for Immunotherapy of Cancer, to initiate an international Immunoscore consortium to assess the prognostic value of total T-lymphocyte and cytotoxic T-lymphocyte tumour infiltrate. The international Immunoscore consortium of expert pathologists and immunologists identified a strategy for an international multicentre study to validate the consensus Immunoscore in patients with stage I–III colon cancer. The purpose of the study was to agree on how to harmonise the Immunoscore assay, to demonstrate the feasibility and reproducibility of the Immunoscore, to demonstrate the utility of the Immunoscore to predict patients with stage II colon cancer at high risk of recurrence, and to validate the prognostic value of the Immunoscore in routine clinical settings.

Implications of all the available evidence

Compared with existing prognostic tools, the consensus Immunoscore can be used to better define the prognosis of cancer patients, better identify patients at high risk of tumour recurrence (including patients with stage II colon cancer), and stratify patients who could benefit from adjuvant therapies. The consensus Immunoscore study represents the largest international consortium validating a standardised immune parameter to stratify patients with cancer. The Immunoscore had a prognostic value superior to that of existing tumour parameters. This initiative and these results support the implementation of the consensus Immunoscore as a new component for a TNM-Immune classification of cancer.

A revolutionary change is taking place in oncology by evaluating, and activating with immunotherapy, the pre-existing intra-tumoral immunity of patients.26, 27 The pre-existing intratumoral immune profile can now be assessed by digital pathology. An international consortium was initiated with the support of the Society for Immunotherapy of Cancer (SITC)28 to validate the consensus Immunoscore in clinical practice for patients with stage I–III colon cancer. Here we report the final results of an analysis of colonic tumours to assess the relation between Immunoscore and prognosis and to compare the Immunoscore with existing prognostic risk parameters, including microsatellite instability (MSI) status.

Section snippets

Study design and patients

An international consortium of 14 expert centres in 13 countries in North America, Europe, and Asia (appendix) was initiated to evaluate the standardised Immunoscore assay in primary tumours from patients with stage I–III colon cancer (appendix). After stratification by centre, T stage, N stage, and relapse, patients from Switzerland, Germany, France, the USA, the Czech Republic, and Canada for whom data were available before Jan 1, 2016 were randomly assigned (1:1) to a training set and an

Results

Tumour samples from 3539 patients with AJCC/UICC TNM stage I–III colon cancer were collected between 2013 and 2015, and Immunoscore data were retrieved between 2013 and 2016. 357 patients were excluded after biomarker quality control, and 577 patients were excluded after clinical data quality control. Samples from 2681 patients were included in the analyses (700 patients in the training set, 636 patients in the internal validation set, and 1345 patients in the external validation set [including

Discussion

Since the early 1900s, immune infiltration of cancers has been suspected to be a positive factor for patient outcome;30 however, these insights did not have a major influence on cancer classification or clinical decision making. The recent demonstration of the prognostic importance of the immune contexture,7 together with new image assessment software to enumerate cells in tumours, has led the SITC to promote an international validation of the derived Immunoscore assay.28

This study complied

References (33)

  • L Sobin et al.

    TNM classification of malignant tumors

    (2002)
  • J Galon et al.

    Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

    J Pathol

    (2014)
  • J Guinney et al.

    The consensus molecular subtypes of colorectal cancer

    Nat Med

    (2015)
  • WH Fridman et al.

    The immune contexture in human tumours: impact on clinical outcome

    Nat Rev Cancer

    (2012)
  • J Galon et al.

    Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

    Science

    (2006)
  • WS Lee et al.

    Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer

    Cancer

    (2010)
  • Cited by (1430)

    View all citing articles on Scopus

    Dr Sargent died in September, 2016

    View full text